Skip to main content
. 2022 Dec 13;15(1):2153409. doi: 10.1080/19420862.2022.2153409

Figure 2.

Figure 2.

Tumor inhibition potency of JS007 in syngeneic tumor model. (a) The in vivo tumor suppression efficacy of JS007 in hCTLA-4 knock-in mice of the C57BL/6 background by inoculation of MC38 tumor cell line. JS007 was injected i.p. twice a week in low dose groups (0.1 mg/kg) and high dose group (1 mg/kg). 1 mg/kg of ipilimumab or hIgG1 isotype antibodies were injected as control. The data with each dot shows the average tumor volume of the group while the SE was presented as longitudinal bars. (b) The tumor weight of each group at the end of the experiment was shown. (c) The in vivo tumor suppression efficacy of JS007 in hCTLA-4 knock-in mice of the BALB/c background by inoculation of H22 tumor cell line. JS007 was injected i.p. twice a week in two groups, 0.03 mg/kg low dose group and 0.1 mg/kg high dose group. 0.1 mg/kg of ipilimumab or hIgG1 isotype antibodies were injected as control. (d) The tumor weight of each H22 syngeneic tumor group at the end of the experiment was shown. Statistical analysis was calculated with Wilcoxon paired T test. *, p < .05; ns, p > .05.